http://deals.venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/ News About Tech, Money and Innovation Sun, 22 Nov 2009 19:46:42 +0000 http://wordpress.org/?v=2.8.5 hourly 1 http://deals.venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/comment-page-1/#comment-653508 VentureBeat » Agensys sells out to Astellas for $387M — but is it a pig in a poke? Wed, 28 Nov 2007 02:06:31 +0000 http://venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/#comment-653508 [...] an early stage biotech whose technology has barely reached the proof-of-concept stage. When Merck paid $350 million for NovaCardia in July, it was getting a company with a new heart drug that had already completed [...] [...] an early stage biotech whose technology has barely reached the proof-of-concept stage. When Merck paid $350 million for NovaCardia in July, it was getting a company with a new heart drug that had already completed [...]

]]> http://deals.venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/comment-page-1/#comment-632802 VentureBeat » Life sciences briefing: Wednesday, Nov. 14, 2007 Wed, 14 Nov 2007 18:13:45 +0000 http://venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/#comment-632802 [...] its portfolio companies were acquired this year — Avidia, by Amgen; NimbleGen, by Roche; and NovaCardia, by Merck (the links point to our coverage). Four of its portfolio companies — Hansen Medical, Sirtris [...] [...] its portfolio companies were acquired this year — Avidia, by Amgen; NimbleGen, by Roche; and NovaCardia, by Merck (the links point to our coverage). Four of its portfolio companies — Hansen Medical, Sirtris [...]

]]> http://deals.venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/comment-page-1/#comment-556152 VentureBeat » Life sciences briefing: Friday, Sept. 28, 2007 Fri, 28 Sep 2007 17:10:20 +0000 http://venturebeat.com/2007/07/25/merck-buys-cardio-drug-maker-novacardia-for-350m/#comment-556152 [...] draws on $20M for heart drug — Fresh from the sale of NovaCardia to Merck (see our coverage here), officials of that heart-drug company founded a second startup, San Diego’s aptly named [...] [...] draws on $20M for heart drug — Fresh from the sale of NovaCardia to Merck (see our coverage here), officials of that heart-drug company founded a second startup, San Diego’s aptly named [...]

]]>